netupitant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
neurokinin NK1 (substance P) receptor antagonist	4898	290297-26-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: Ro 67-3189/000 netupitant	Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors. Delayed emesis has been largely associated with the activation of tachykinin family neurokinin 1 (NK-1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses. Molecular weight: 578.60 Formula: C30H32F6N4O CLOGP: 6.76 LIPINSKI: 2 HAC: 5 HDO: 0 TPSA: 39.68 ALOGS: -5.31 ROTB: 7 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

Ro 67-3189/000
netupitant

Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors. Delayed emesis has been largely associated with the activation of tachykinin family neurokinin 1 (NK-1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses.

Molecular weight: 578.60
Formula: C30H32F6N4O
CLOGP: 6.76
LIPINSKI: 2
HAC: 5
HDO: 0
TPSA: 39.68
ALOGS: -5.31
ROTB: 7

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
Vd (Volume of distribution)	5.54 L/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	34.28 hours	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.83 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 5 of 5 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
May 27, 2015	EMA	Helsinn Birex Pharmaceuticals Ltd
Oct. 10, 2014	FDA	HELSINN HLTHCARE

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Subclavian artery occlusion	42.28	36.61	6	878	168	79743336
Hypomagnesaemia	39.48	36.61	16	868	46895	79696609

Showing 1 to 2 of 2 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:55350	neurokinin-1 receptor antagonists
FDA EPC	N0000175786	Substance P/Neurokinin-1 Receptor Antagonist
FDA MoA	N0000010262	Neurokinin 1 Antagonists
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000190113	Breast Cancer Resistance Protein Inhibitors

Showing 1 to 7 of 7 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chemotherapy-induced nausea and vomiting	indication	236084000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.9	Basic
pKa2	3.35	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
300MG;EQ 0.5MG BASE	AKYNZEO	HELSINN HLTHCARE	N205718	Oct. 10, 2014	RX	CAPSULE	ORAL	11559523	Nov. 18, 2030	METHOD OF TREATING EMESIS
300MG;EQ 0.5MG BASE	AKYNZEO	HELSINN HLTHCARE	N205718	Oct. 10, 2014	RX	CAPSULE	ORAL	8623826	Nov. 18, 2030	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
300MG;EQ 0.5MG BASE	AKYNZEO	HELSINN HLTHCARE	N205718	Oct. 10, 2014	RX	CAPSULE	ORAL	9186357	Nov. 18, 2030	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
300MG;EQ 0.5MG BASE	AKYNZEO	HELSINN HLTHCARE	N205718	Oct. 10, 2014	RX	CAPSULE	ORAL	9943515	Nov. 18, 2030	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
300MG;EQ 0.5MG BASE	AKYNZEO	HELSINN HLTHCARE	N205718	Oct. 10, 2014	RX	CAPSULE	ORAL	10828297	Dec. 17, 2030	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
300MG;EQ 0.5MG BASE	AKYNZEO	HELSINN HLTHCARE	N205718	Oct. 10, 2014	RX	CAPSULE	ORAL	9271975	Sept. 9, 2031	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY

Showing 1 to 6 of 6 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Substance-P receptor	GPCR	P25103	NK1R_HUMAN	ANTAGONIST	Ki	9.02		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
015714	NDDF
1552337	RXNORM
30612	MMSL
4033795	VUID
4033795	VANDF
5742	IUPHAR_LIGAND_ID
6451149	PUBCHEM_CID
716123009	SNOMEDCT_US
7732P08TIR	UNII
8409	INN_ID

Showing 1 to 10 of 19 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
AKYNZEO	HUMAN PRESCRIPTION DRUG LABEL	2	69639-101	CAPSULE	300 mg	ORAL	NDA	26 sections
AKYNZEO	HUMAN PRESCRIPTION DRUG LABEL	2	69639-101	CAPSULE	300 mg	ORAL	NDA	26 sections
AKYNZEO	HUMAN PRESCRIPTION DRUG LABEL	2	69639-101	CAPSULE	300 mg	ORAL	NDA	26 sections

Showing 1 to 3 of 3 entries

Previous1Next